Case Report: Recurrent retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient [version 2; peer review: 2 approved with reservations]

Previous title: Case Report: Retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient

Marwa Ben Brahim¹, Sondes Arfa¹, Fadia Boubaker¹, Jihen Chelly¹, Wafa Ammari², Sonia Hammami³, Fatma Arbi¹, Olfa Berriche¹, ⁴

¹Department of Internal Medicine and Endocrinology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia
²Department of Ophthalmology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia
³Department of Internal Medicine and Endocrinology, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, 5000, Tunisia
⁴Biochemistry Laboratory, LR12ES05 LR-NAFS Nutrition-Functional Food and Vascular Health, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia

Abstract
Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterized by widespread clinical manifestations and immunological disorders. A myriad of ocular manifestations can be seen in patients with SLE. The most vision-threatening complication is vaso-occlusive retinopathy including retinal vein occlusion (RVO). RVO associated with SLE is well described in the literature and its association with antiphospholipid antibodies is recognized. However, RVO as the initial manifestation of SLE is scarcely reported. Herein, we report the first case of recurrent RVO as the revealing manifestation of SLE in a 40-year-old male patient. He had two consecutive episodes of decreased vision. Ophthalmologic examination disclosed a branch retinal vein occlusion the first time and a central retinal vein occlusion the second time. The diagnosis of SLE was established based on clinical and immunological criteria. He was prescribed antiplatelet therapy, hydroxychloroquine at 5.5 mg/kg/day, and intravitreal anti-vascular endothelial growth factor (VEGF) antibodies regimen. He slowly improved under treatment.
Keywords
Retinal vein occlusion, Systemic Lupus Erythematosus, Male patient, Intra-vitreal anti-vascular endothelial growth factor antibodies treatment, case report

Corresponding author: Marwa Ben Brahim (benbrahim.marwa24@gmail.com)

Author roles: Ben Brahim M: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Methodology, Resources, Visualization, Writing – Original Draft Preparation; Arfa S: Conceptualization, Data Curation, Investigation, Methodology, Visualization, Writing – Review & Editing; Boubaker F: Resources, Software, Validation; Chelly J: Resources, Visualization; Ammari W: Data Curation, Resources, Software, Visualization; Hammami S: Formal Analysis, Resources, Writing – Review & Editing; Arbi F: Resources, Software, Visualization; Berriche O: Formal Analysis, Resources, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Ben Brahim M et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ben Brahim M, Arfa S, Boubaker F et al. Case Report: Recurrent retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient [version 2; peer review: 2 approved with reservations] F1000Research 2021, 10:761 https://doi.org/10.12688/f1000research.55189.2

First published: 05 Aug 2021, 10:761 https://doi.org/10.12688/f1000research.55189.1
Introduction
Retinal vein occlusion (RVO) is a common retinal vascular disorder that, if left untreated, can lead to vision loss. Classic risk factors are hypertension, hyperlipidemia and diabetes mellitus. Systemic and inflammatory diseases such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome were found to be associated with the development of RVO. RVO associated with SLE is well described in the literature and its association with antiphospholipid antibodies is recognized. However, RVO as the initial manifestation of SLE is very uncommon. Herein we report a unique case of recurrent RVO as the initial presentation of SLE in a male patient.

Case report
A 40-year-old Tunisian man, with no family history of autoimmune diseases and a personal medical history of hypertension treated with angiotensin-converting enzyme inhibitor, was admitted to the Ophthalmology Department of Taher Sfar University Hospital with blurred vision in the right eye. On detailed physical examination, he had no fever, arthritis, or chest complaints. On ophthalmologic examination, the best corrected visual acuity was 20/20, and a retinal branch vein occlusion in the right eye was disclosed. He was treated with aspirin (100 mg/day) associated with equilibration of his hypertension.

One year later, he experienced another episode of blurred and decreased vision in the same eye. Physical examination was unremarkable. A skin exam revealed he had an erythema over the malar area. His blood pressure was normal. Fundus examination disclosed central retinal vein occlusion, superficial flame-shaped retinal hemorrhages, and macular oedema (Figure 1). Fluorescein angiography (FA) demonstrated vascular tortuosity, retinal hemorrhage, and cotton wool spots on the right eye (Figure 2). Spectral-domain optical coherence tomography demonstrated cystoid macular oedema (Figure 3). The left eye examination showed normal sizes of the retinal vessels and retina. A refraction study showed a best corrected visual acuity at 20/70 in the right eye and 20/20 in the left eye. On laboratory investigations, a blood test showed platelets: 229 * 10^9/l, leukocytes: 9 * 10^9/l, and hemoglobin level: 13.5 g/dl. Erythrocyte sedimentation rate was 30 serum creatinine was normal. Moreover, urinalysis did not show proteinuria.

Autoantibodies tests revealed positive antinuclear antibodies (1: 800), anti-DNA antibodies, anti-nucleosomes antibodies, and slightly positive anti-citrullinated protein antibodies and rheumatoid factors. Antiphospholipid antibodies screening displayed high titer (> 40 UI) of IgG antiprophospholipid antibodies and
IgG antiβ2 glycoprotein antibodies. Total blood complement, C3, C4, protein S, protein C antithrombin III, and homocysteinemia levels were normal. The patient was also negative for factor V mutation. Echocardiographic excluded pericardial effusion. The diagnosis of SLE was established based on clinical and immunological criteria including malar rash, positive anti-nuclear antibodies, anti-DNA antibodies, and antiphospholipid antibodies.

The patient was started with hydroxychloroquine at 5.5 mg/kg/day and intra-vitreal anti-vascular endothelial growth factor (VEGF) antibodies regimen, in combination with aspirin (100 mg/day). The patient is still regularly taking his treatment without significant side effects. His vision has slowly improved under treatment. The patient remained under close observation. After two years of follow up, a refraction study showed a stable visual acuity.

Discussion
The atypical clinical presentation of SLE, in a male patient with a medical history of hypertension, and without any clinical objective criteria, led to the delay of the diagnosis of this autoimmune disease. The diagnosis was made after a second retinal vein occlusion. The patient had cutaneous involvement concomitantly with ocular complication. He had immunological criteria including positive antinuclear antibodies, anti-DNA antibodies and antiphospholipid antibodies which made the diagnosis clearer.

SLE is a chronic and autoimmune disease characterized by widespread clinical manifestations and immunological disorders. It occurs in both genders but it is much more common in females than males, with female: male sex-ratio of 8:1 to 15:1. Male patients have a higher prevalence of life-threatening manifestations including lupus nephritis, central neurological system involvement and hemolytic anemia. Regarding immunological features, anti-phospholipid antibodies were found to be more frequent in male SLE patients. Thus, it would be expected that they present an increased risk of thromboembolic manifestations and antiphospholipid syndrome, which could worsen the course of the illness and increase the mortality rates. We report a case of SLE associated with antiphospholipid antibodies in a male patient. He presented a recurrent RVO as the first manifestation of the disease making this case unique.

A myriad of ocular manifestations can be seen in patients with SLE including keratoconjunctivitis, scleritis, episcleritis, retinopathy, choroidopathy, orbital and lachrymal system disorders. The most common ocular manifestation is keratoconjunctivitis but the most visually-threatening is retinopathy. The prevalence of lupus retinopathy varies from 3% to 28%. The most common manifestations of lupus retinopathy are cotton wool spots, retinal hemorrhage and optic disk oedema. Vaso-occlusive retinopathies is a subset of retinal vasculopathy, including retinal artery or vein occlusions which are a rare but severe complication. The vascular retinopathy in SLE results from immune complex mediated vascular injuries and micro-vascular thrombosis. Patients with retinal vessel occlusion seem to have a poorer visual prognosis.

Patients with SLE have a higher prevalence of developing RVO than the general population. A higher incidence of antiphospholipid antibodies in SLE patients with RVO has been reported. In our case, antiphospholipid antibodies were positive with a high titer. Typically, RVO occurs in the first four years follow-up of SLE. Retinal vasculitis was scarcely reported as the initial manifestation of SLE. As far as we know, this would be the first case of a recurrent RVO as the primary presentation of SLE to be reported in literature.

Regarding the treatment of RVO in patients with SLE, anti-coagulation and anti-platelet therapies have contributed to the stabilization of the retinal occlusion and the prevention of recurrent thrombosis either used separately or combined. The use of an immunsuppressant is still controversial due to the lack of evidence about its effects in improving the visual acuity and the retinal vascular occlusion recurring. Intravitreally administrated anti-VEGF antibodies were introduced in the treatment regimen of RVO. Its main desired effect is to reduce the macular edema, which is the major cause of decreased visual acuity in patients with RVO. Our patient received a combination of anti-platelet therapy and anti-VEGF antibodies. Clinical improvement was achieved under this treatment.

Conclusion
SLE in males may have an atypical presentation. This often leads to a diagnostic and therapeutic delay. In this paper, we have reported a unique case of SLE in a male patient presenting with a severe and sight-threatening ocular complication. The diagnosis was overlooked, as the patient did not have any clinical criteria of SLE initially. Our case report’s core contribution is to raise awareness about the possible atypical and severe presentation of SLE in men.

Consent
Written informed consent for publication of their clinical details and clinical images was obtained from the patient.

Data availability statement
All data underlying the results are available as part of the article and no additional source data are required.
PubMed Abstract | Publisher Full Text
PubMed Abstract | Publisher Full Text | Free Full Text
PubMed Abstract | Publisher Full Text | Free Full Text
PubMed Abstract | Publisher Full Text
PubMed Abstract | Publisher Full Text
PubMed Abstract | Publisher Full Text
PubMed Abstract | Publisher Full Text
Publisher Full Text
PubMed Abstract | Publisher Full Text | Free Full Text
PubMed Abstract
PubMed Abstract | Publisher Full Text
PubMed Abstract | Publisher Full Text
Matias Iglicki
Private Retina Practice, University of Buenos Aires, Buenos Aires, Argentina

Marwa Ben Brahim et al. present an interesting study about Retinal vein occlusion (RVO) as the first clinical manifestation of systemic lupus erythematosus (SLE) in a male patient. The study results certainly suggest to some degree that the RVO as the initial manifestation of SLE is scarcely reported.

Besides how the magnitude of these data add new findings compare to the current standard can not be determined only based on this study. The results are encouraging and further study is warranted.

Here some relevant points:
1. Please add on keywords - these do not match with the manuscript.

2. The authors should express why it is relevant for an RVO patient to link Retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient? What does it change for the current standard of care?

3. The authors should explain why their findings make a difference for ophthalmologists around the world and for the readers of F1000Research.

4. The authors should explain the source of the information and what criteria they used for adding it to the paper. Were the assessors masked? What was the ICC (Inter class Correlation) between them in order to analyze the data? Was the randomization digitalized?

5. Please add in the introduction that papers have been published showing how the Optical Coherence Tomography (OCT) and new devices lead us to proper diagnoses in Retinal diseases - add one line in the introduction of this and also in the discussion section. These papers should be described in the general considerations. See references\(^1,2,3\).

6. Please add how and how long takes for a retina specialist to link and ask the patient about
SLE and other Rheumatology and Rheumatic Diseases.

7. Results could be misinterpreted - add a short summary of the similarities in different devices and also add different OCT modalities, etc., and what can be improved in the process of detecting RVO is mandatory in the discussion section i.e wide-field angiography, different types of OCT modalities OCT angiography (OCTa).

8. Please apply correction for misspelling and English grammar.

References

Is the background of the case's history and progression described in sufficient detail? 
Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes? 
Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment? 
Partly

Is the case presented with sufficient detail to be useful for other practitioners? 
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** DME, RVO, NAMD and retina surgical cases

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 17 August 2021
https://doi.org/10.5256/f1000research.58746.r91272
Bouomrani Salem
1 Sfax Faculty of Medicine, University of Sfax, Sfax, 3029, Tunisia
2 Department of Internal medicine, Military Hospital of Gabes, Gabes, 6000, Tunisia

The authors provide an interesting and original Case Report of retinal venous occlusion revealing systemic lupus erythematosus in a man. This observation is distinguished by the initial atypical clinical manifestation, male sex, and recurrence of retinal occlusion. This case is therefore the first to report recurrent retinal venous occlusion as an initial manifestation of lupus.

Some comments are however useful to improve the quality of this manuscript:

1. Title:
   ○ Replace the proposed title with "recurrent retinal vein occlusion as..." to highlight the recurrent character which is the originality of this observation.

2. Abstract:
   ○ Replace “primary” by initial or revealing.

3. Keywords:
   ○ Adapt the list of keywords to international standards: remove “patient” from “male patient”, remove “case report”, remove “intra- vitreal and treatment” from “Intra-vitreal anti-vascular endothelial growth factor antibodies treatment”.

4. Case Report:
   ○ Specify the anti-hypertensive treatment received by the patient (possibility of induced lupus)?
   ○ Replace "caucasian" by "Tunisian".
   ○ Remove "s" from "rheumatoid factors",
   ○ Add, if possible, a photo of the patient's malar erythema.
   ○ If possible, give the results of the explorations made to support the diagnosis of systemic lupus erythematosus: cardiac ultrasound (lupus pericarditis? which is asymptomatic in 30% of cases), cerebral MRI (infra-clinical neurolupus? Especially the association with retinal vasculitis is noted in more than 70% of cases[1]), and urinalysis?.
   ○ Specify, if they were carried out, the results of the following tests: factor V mutation? (main thrombophilia causing venous thrombosis in Tunisia), and homocysteinemia? (hyperhomocysteinemia may be an added risk factor for retinal vein occlusions during SLE (1 patient/3 in Kumar K et al series[2]).

5. Discussion:
   ○ Replace "primary" by initial or revealing.
   ○ Discuss the significance of anti-CCP antibodies in this observation: associated rheumatoid
Is the background of the case's history and progression described in sufficient detail?
Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Partly

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Yes

Is the case presented with sufficient detail to be useful for other practitioners?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Connective tissue disease, autoimmunity, immunogenic.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 27 Sep 2021
Marwa Ben Brahim, Taher Sfar University Hospital, University of Monastir, Mahdia, Tunisia

1. Done

2. Done

3. Done, the keyword "case report" was kept because it has to be mentioned.

4. We, unfortunately, do not have any pictures of the patient's malar rash. Since the patient had not had any neurological symptoms, we did not demand a Brain-MRI. We have assed further details about the laboratory investigation.

5. Done. The patient had slightly positive anti-citrullinated protein antibodies and rheumatoid factor without bone erosion or joint stiffness or deformity evoking the diagnosis of rhupus. In fact, the positivity of anti-CCP can be seen in 10-15% of patients with SLE without an association to rheumatoid arthritis.

6. We rephrased "delay in making the...." as you suggested. We corrected typical by atypical as you suggested. We have emphasized the recurrent and revealing character of the retinal vein occlusion in all parts of the paper.

**Competing Interests:** No competing interests.